Richard Forshee, PhD
Associate Director for Research/Acting Deputy Director, FDA CBER OBPV
Reported Dr. Szarfman's mortality-signal findings to Dr. Marks in July 2021 and in 2022 expressed concerns about her published paper on masking.
Timeline appearances (7)
- analysis
Szarfman organizes a virtual meeting on a new safety data mining methodology designed by DuMouchel.
- analysis
Szarfman presents RGPS to Marks and other CBER officials, calling MGPS not state of the art.
- analysis
Szarfman resends RGPS analysis on acute myocardial infarction and invites Forshee to collaborate.
- analysis
Szarfman calls Forshee to discuss increased risk of mortality following COVID-19 vaccination.
- analysis
Szarfman writes Forshee that RGPS shows statistically significant mortality signals for Pfizer and Moderna vaccines.
- internal
Forshee forwards Szarfman's mortality findings to Marks, expressing concern about her interpretation.
- publication
Forshee notifies Marks and Anderson that FDA officials are addressing issues with Szarfman's published paper.
Quotes (2)
-
"she and Bill DuMouchel had found an increased risk of mortality following COVID-19 vaccination using data mining methods."
-
"we have just learned that Dr. Szarfman is a co-author on a recently published paper based on COVID-19 vaccines and VAERS. We believe there are a number of issues with the paper and its findings, and we are discussing how to best respond."